Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Tofacitinib 5 mg twice daily
DRUG
2 trials
Sponsors
Yale University
, University Hospital, Toulouse
Conditions
Cutaneous Sarcoidosis
Granuloma Annulare
Rhumatoid Arthisis
Phase 1
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
Completed
NCT03910543
Yale University
Cutaneous Sarcoidosis, Granuloma Annulare
Start: 2019-04-11
End: 2021-06-01
Updated: 2021-07-14
Phase 4
JAK Inhibitor Dose TAPering Strategy Study
Not yet recruiting
NCT06687551
University Hospital, Toulouse
Rhumatoid Arthisis
Start: 2025-01-01
End: 2029-04-01
Target: 308
Updated: 2024-11-13
Related Papers
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis
Nature Communications
2022-06-06
107 citations
Ulcerated necrobiosis lipoidica successfully treated with tofacitinib
International Journal of Dermatology
2021-11-16
16 citations
Treatment of granuloma annulare with tofacitinib 2% ointment
JAAD Case Reports
2019-12-30
31 citations